Indeed, NRF2/Kelch-like ECH-associated protein 1 (KEAP1) pathway, which scavenges ROS, promotes NF-κB and NFTAc1 and regulates osteoclastogenesis in vitro and in vivo, suggesting that NRF2 activators as a new therapeutic target of osteoporosis [67–69]. This evidence concerns the gene KEAP1 and osteoporosis.